Breaking News

Tufts CSDD Pegs Drug R&D to Market Costs at $2.6 billion

Costs attributed to clinical complexity, larger trials, and efforts to accommodate payer demands

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The average cost to develop and gain marketing approval for a new drug is now estimated to be $2.6 billion, according to recent analysis by the Tufts Center for the Study of Drug Development of the Journal of Health Economics. The analysis was based, in part, on information from 10 pharma companies on 106 randomly selected drugs that were first tested in human subjects from 1995 to 2007. The article, included in the May issue of the Journal of Health Economics, contains more detailed analyse...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters